ORBAS

Olmesartan Medoxomil

CARDIOVASCULAR

INDICATION

ORBAS(Olmesartan Medoxomil) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

DOSAGE AND ADMINISTRATION

Adult: Hypertension-The usual starting dose of ORBAS (Olmesartan Medoxomil) is 20 mg once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be increased after 2 weeks to 40 mg. ORBAS (Olmesartan Medoxomil) may be administered with or without food. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance < 40 mL/min) or with moderate to marked hepatic dysfunction. If blood pressure is not controlled by ORBAS (Olmesartan Medoxomil) alone, a diuretic may be added. ORBAS (Olmesartan Medoxomil) may be administered with other antihypertensive agents. Pediatric Hypertension (6 to 16 years of age)- The usual recommended starting dose of ORBAS (Olmesartan Medoxomil) is 10 mg once daily for patients who weigh 20 to < 35 kg or 20 mg once daily for patients who weigh > 35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to a maximum of 20 mg once daily for those who weigh < 35 kg or 40 mg once daily for patients who weigh > 35 kg.  

COMPOSITION

ORBAS 20: Each film-coated tablet contains Olmesartan Medoxomil INN 20 mg. ORBAS 40: Each film-coated tablet contains Olmesartan Medoxomil INN 40 mg.